Results 101 to 110 of about 36,964 (190)

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients. [PDF]

Blood Cancer J
Fathima S, Rokach L, Ghosoun N, Rezasoltani M, Ilyas R, Alsugair A, McCullough K, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Punwani N, Sproat L, Khera N, Arana Yi C, Tefferi A, Gangat N.   +29 more
europepmc   +1 more source

Vitexin induces apoptosis and enhances daunorubicin efficacy in acute leukemia via modulation of the HIF-1α/Bcl-2/caspase-3 pathway. [PDF]

Sci Rep
Jirawatpraphakorn C, Tanyong D, Jaree A, Owattanapanich W.   +3 more
europepmc   +1 more source

Real-Time Single-Cell Measurement and Kinetic Modeling of Daunorubicin Uptake in Multidrug-Resistant Leukemia Cells Using a Microfluidic Biochip. [PDF]

Pathophysiology
Chen Y, Chiem M, Joshi N, Li PCH.
europepmc   +1 more source

Retraction Note: Mathematical modeling and statistical analysis of breast cancer drugs using M-polynomial indices for the physical properties. [PDF]

Sci Rep
Tawhari QM, Naeem M, Maqbool S, Rauf A, Oyelakin O.   +4 more
europepmc   +1 more source

Autocrine Motility Factor-Derived Tetradecapeptides as Dual-Action Chemosensitizers: Bridging Cell Competition Mechanisms with Clinical MDR Reversal in Hematological Malignancies. [PDF]

Oncol Res
Kim C, Jung YJ, Son DH, Kim NY, Kim SG, Park HS.   +5 more
europepmc   +1 more source

Daunorubicin‐induced hyperpigmentation [PDF]

British Journal of Haematology, 2010
Raj R, Pol, Andrew, Wright, Anita, Hill
openaire   +2 more sources

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy. [PDF]

Am J Hematol
Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M, Röllig C.   +44 more
europepmc   +1 more source

Flow cytometry-based targeted diagnostics for rapid assessment of daunorubicin resistance in acute myeloid leukemia. [PDF]

Sci Rep
Kaczorowska A, Sareło P, Gąsior-Głogowska M, Zioło E, Karpiński P, Łaczmański Ł, Sobas M, Wróbel T, Podbielska H, Kopaczyńska M, Kałas W.   +10 more
europepmc   +1 more source

Investigating of harmane, harmine, and norharman as inhibitors of MDR1 and MRP1 to overcome chemotherapy resistance in cancer cells. [PDF]

Sci Rep
Abdi N, Banitalebi A, Heidari R, Zahedian S, Mirzaei SA, Elahian F.   +5 more
europepmc   +1 more source

Is creatine kinase a valid aid in early cardiac muscle damage detection during treatment for childhood acute lymphoblastic leukemia? A case report. [PDF]

Front Oncol
Fazio G, Intra J, Montini O, Bettini LR, Gotti G, Sala A, Bungaro S, Cazzaniga G, Rizzari C, Balduzzi A, Casati M.   +10 more
europepmc   +1 more source